Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. (Record no. 6071)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03895nam a22003617a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 210217s20212021 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 0023-852X |
| 024 ## - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1002/lary.29343 [doi] |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| PMID | 33405268 |
| 245 ## - TITLE STATEMENT | |
| Title | Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. |
| 251 ## - Source | |
| Source | Laryngoscope. 2021 Jan 06 |
| 252 ## - Abbreviated Source | |
| Abbreviated source | Laryngoscope. 2021 Jan 06 |
| 253 ## - Journal Name | |
| Journal name | The Laryngoscope |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Year | 2021 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Manufacturer | FY2021 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
| Publication status | aheadofprint |
| 266 ## - Date added to catalog | |
| Date added to catalog | 2021-02-17 |
| 501 ## - WITH NOTE | |
| Local holdings | Available online from MWHC library: 1997 - present, Available in print through MWHC library: 1996 - 2003 |
| 520 ## - SUMMARY, ETC. | |
| Abstract | CONCLUSION: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. |
| 520 ## - SUMMARY, ETC. | |
| Abstract | LEVEL OF EVIDENCE: 5. Laryngoscope, 2021. Copyright (c) 2021 The American Laryngological, Rhinological and Otological Society, Inc. |
| 520 ## - SUMMARY, ETC. | |
| Abstract | METHODS: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up. |
| 520 ## - SUMMARY, ETC. | |
| Abstract | OBJECTIVES/HYPOTHESIS: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. |
| 520 ## - SUMMARY, ETC. | |
| Abstract | RESULTS: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18). |
| 520 ## - SUMMARY, ETC. | |
| Abstract | STUDY DESIGN: Delphi method-based survey series. |
| 546 ## - LANGUAGE NOTE | |
| Language note | English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | IN PROCESS -- NOT YET INDEXED |
| 657 ## - INDEX TERM--FUNCTION | |
| Medline publication type | Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Local Authors | Grant, NazaneenKW - MedStar Medical Group |
| 790 ## - Authors | |
| All authors | Balakrishnan K, Baroody FM, Best SR, Bock JM, Boss EF, Bower CM, Buckingham J, Campisi P, Chen SF, Clarke JM, Clarke KD, Cocciaglia A, Cotton RT, Cuestas G, Davis KL, De Alarcon A, DeFago VH, Derkay CS, Dikkers FG, Dossans I, Florez W, Fox E, Friedman AD, Grant N, Hamdi O, Hogikyan ND, Johnson K, Johnson LB, Johnson RF, Kelly P, Klein AM, Lam D, Lawlor CM, Leboulanger N, Levy AG, Licameli GR, Long S, Lott DG, Manrique D, McMurray JS, Meister KD, Messner AH, Mohr M, Mortelliti AJ, Mudd P, Novakovic D, Ongkasuwan J, Peer S, Piersiala K, Prager JD, Pransky SM, Preciado D, Raynor T, Rinkel RNPM, Rodriguez H, Rodriguez VP, Russell J, Scatolini ML, Scheffler P, Sidell DR, Smith DF, Smith LP, Smith ME, Smith RJH, Sorom A, Steinberg A, Stith JA, Thompson D, Thompson JW, Varela P, White DR, Wineland AM, Yang CJ, Zdanski CJ, Zur K |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| DOI | <a href="https://dx.doi.org/10.1002/lary.29343">https://dx.doi.org/10.1002/lary.29343</a> |
| Public note | https://dx.doi.org/10.1002/lary.29343 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | Journal Article |
| Item type description | Article |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedStar Authors Catalog | MedStar Authors Catalog | 02/17/2021 | 33405268 | 33405268 | 02/17/2021 | 02/17/2021 | Journal Article |